Loading
Epigenetics and DNA Methylation / Immune Cells in Cancer · Journal article
Cell Death and Disease · August 15, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic study demonstrating that YAP-K90 lactylation regulates nuclear translocation and immune-related gene expression in renal cancer cells, and that HDAC1 inhibition enhances combination therapy response in xenografts. The findings are exploratory and raise a hypothesis about lactylation as a therapeutic target; clinical translation and human efficacy remain unproven.
Journal article. Renal cancer cell lines and xenograft models in huCD34+ HSC NCG mice. Intervention: YAP-K90T transfection (lactylation mimic) and HDAC1 inhibition.
Lysine lactylation (Kla) is downregulated in targeted therapy-resistant renal cancer cells and tissues YAP-K90 lactylation status regulates nuclear translocation and EMT and PD-L1 gene expression HDAC1 was identified as the eraser of YAP-K90 lactylation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest a novel mechanism linking lactylation status to therapy resistance and immune checkpoint expression, but are preliminary. Translation to human renal cell carcinoma treatment requires clinical trial data.
Mechanistic study in cell and animal models identifying a novel post-translational modification pathway; lacks human clinical data or hard clinical outcomes.
As stated by the source record.
These findings suggest a novel mechanism linking lactylation status to therapy resistance and immune checkpoint expression, but are preliminary. Translation to human renal cell carcinoma treatment requires clinical trial data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Lactylation is a novel lysine acylation modification, and its function and exact mechanisms remain unclear. The responsiveness to combined targeted and immunotherapy continues to be a major challenge in cancer treatment. Here, we discovered that lysine lactylation (Kla) is specifically downregulated in targeted therapy-resistant renal cancer cells and tissues. The lactylation status of YAP at lysine 90 (K90) regulates its nuclear translocation, which is critical for the expression of epithelial-mesenchymal transition (EMT)-related genes and the PD-L1 gene. Furthermore, we identified HDAC1 as the “eraser” of YAP-K90 lactylation. By transfecting YAP-K90T (a lactylation mimic), we enhanced antitumor immune activity. In xenograft models established in huCD34 + HSC NCG mice, we consistently found that HDAC1 inhibition enhances the response to combination therapy by increasing YAP lactylation and promoting CD8⁺ T cell tumor infiltration. These findings reveal lactylation as a key mechanism in targeted drug response and identify inhibiting YAP delactylation as a promising strategy for renal cell carcinoma treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.